Group 1 - The core point of the news is that Beijing Simu Ruike Pharmaceutical Technology Co., Ltd. has submitted an application for public stock issuance and listing on the Beijing Stock Exchange, with the application accepted by the Beijing Securities Regulatory Bureau on September 2, 2025 [1] - The counseling agreement with CITIC Construction Investment Securities was signed on August 29, 2025, and other participating service institutions include Beijing Zhide Law Firm and Tianjian Accounting Firm [2][3] - Simu Ruike, established in 2008, is a Contract Research Organization (CRO) specializing in clinical trial design, operation, and data management, focusing on vaccine, infectious disease, and chronic disease sectors [4] Group 2 - The company previously applied for an IPO on the ChiNext board in June 2022, which was accepted by the Shenzhen Stock Exchange, but later withdrew the application, leading to the termination of the review process on December 28, 2023 [5] - For the fiscal years 2023 and 2024, the company's revenue was reported at 445.93 million yuan and 417.61 million yuan, respectively, with net profits of 95.12 million yuan and 101.66 million yuan [4][6] - The company’s total assets as of December 31, 2024, were 1.03 billion yuan, with total equity of 714.73 million yuan, and a debt-to-asset ratio of 30.53% [6] Group 3 - The company’s major clients include Shanghai Fosun Pharmaceutical, Chongqing Zhifei Biological Products, and China National Pharmaceutical Group, with sales to the top five clients accounting for 58.70% and 62.51% of total revenue in 2023 and 2024, respectively [7][8] - The company’s gross profit margins for its main business were 37.50% and 43.00% for the respective years, indicating some fluctuations [6] - The previous IPO fundraising plan included projects such as the construction of a clinical monitoring service platform and a vaccine research center, with a total intended fundraising of 650 million yuan [11][12]